Seventy-five years after the initial characterization of Crohn's disease (CD), much remains obscure about its etiology. The authors sought to evaluate the incidence trends of the last 25 years worldwide, and the existence of potential correlations with genetic, environmental, and socioeconomic facto
Global rates of Crohn's Disease
β Scribed by Marcel A. Behr; Paul Bruere; Olivia Oxlade
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 149 KB
- Volume
- 14
- Category
- Article
- ISSN
- 1078-0998
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Background: Adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, is approved for the treatment of Crohn's disease (CD) in adults. We evaluated the overall safety profile of adalimumab in global clinical trials in patients with CD. Patients who participated in these tr
Intestinal fibrosis is a common and serious complication of Crohn's disease (CD) and as it can occur at any time during the disease course, it is crucial to identify patients at risk. The aim is not only to understand the pathophysiology of fibrogenesis but to be able to accurately inform subjects a
Schiff' first described a series of children with Crohn's disease in New York in 1945. He took care to exclude other diseases of the gastrointestinal tract with which it might clinically have been mistaken; these included infections by enteropathogenic bacteria and infestations with giardia and amoe